News
More from REDUCE-IT: Icosapent ethyl cuts revascularization by a third
The high-strength eicosapentaenoic acid product reduced revascularizations by one-third in patients at increased cardiovascular risk and...
News
ACE inhibitors and severe COVID-19: Protective in older patients?
A randomized trial is planned after a study showed that fewer older hypertensive patients taking ACE inhibitors were hospitalized with COVID-19....
News
Statins and ICH: new meta-analysis
The risk for cerebral ischemia was significantly lower in those who received statins compared with who did not.
News
New angiotensin studies in COVID-19 give more reassurance
A deluge of new data does not suggest harm with ACE inhibitors and angiotensin blockers in COVID-19 rates or outcomes.
News
Diastolic dysfunction is a common risk factor for cognitive decline
Proposed mechanisms for cognitive decline in patients with systolic dysfunction include low cardiac output, embolic infarctions, and hypoxic...
News
Remdesivir now ‘standard of care’ for COVID-19, Fauci says
The interim results show that time to recovery was 31% faster for patients who received remdesivir than for those who received placebo.
Article
Second trial supports ticagrelor alone in ACS after PCI: TICO
The TICO trial confirms results seen in TWILIGHT showing benefits of stopping aspirin 3 months after stenting.
News
UK TAVI: Similar outcomes to surgery in real world
The trial confirms that the results of previous trials in low- to intermediate-risk patients can also be replicated in real-world clinical...
News
TAILOR-PCI: Clopidogrel genotyping trial narrowly misses endpoint
The trial missed its ambitious primary endpoint of a 50% reduction in cardiovascular events, but experts felt that it still should change practice...
News
Dramatic rise in hypertension-related deaths in the United States
The ‘alarming’ increase in hypertension-related deaths between 2007 and 2017, was particularly prominent in the rural South.
News
First clinical evidence of neuroprotection in acute stroke?
LOS ANGELES – A potential neuroprotectant was beneficial for patients with ischemic stroke undergoing thrombectomy in the ESCAPE-NA1 trial.
News
TNK dose in large-vessel stroke: 0.25 mg/kg is sufficient
New data from a second EXTEND-IA TNK (tenecteplase) trial clarify the optimum dose of the bolus thrombolytic for use in ischemic stroke.